MA29975B1 - Antagonistes de la neuropiline - Google Patents

Antagonistes de la neuropiline

Info

Publication number
MA29975B1
MA29975B1 MA30971A MA30971A MA29975B1 MA 29975 B1 MA29975 B1 MA 29975B1 MA 30971 A MA30971 A MA 30971A MA 30971 A MA30971 A MA 30971A MA 29975 B1 MA29975 B1 MA 29975B1
Authority
MA
Morocco
Prior art keywords
neuropilin
antagonists
variants
diagnostic
antibodies
Prior art date
Application number
MA30971A
Other languages
English (en)
Inventor
Ryan J Watts
Yan Wu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA29975B1 publication Critical patent/MA29975B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION SE RAPPORTE À DE NOUVEAUX ANTICORPS DIRIGÉS CONTRE NRP1 ET À DES VARIANTS DE CES DERNIERS, QUI POSSÈDENT DES CARACTÉRISTIQUES STRUCTURELLES ET FONCTIONNELLES UNIQUES. L'INVENTION A ÉGALEMENT TRAIT À DES UTILISATIONS DESDITS ANTICORPS DANS DES APPLICATIONS DE RECHERCHE, DIAGNOSTIQUES ET THÉRAPEUTIQUES.
MA30971A 2005-11-08 2008-05-30 Antagonistes de la neuropiline MA29975B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73479805P 2005-11-08 2005-11-08
US82056106P 2006-07-27 2006-07-27

Publications (1)

Publication Number Publication Date
MA29975B1 true MA29975B1 (fr) 2008-11-03

Family

ID=38023965

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30971A MA29975B1 (fr) 2005-11-08 2008-05-30 Antagonistes de la neuropiline

Country Status (20)

Country Link
US (5) US7994286B2 (fr)
EP (2) EP1951758A2 (fr)
JP (2) JP5197376B2 (fr)
KR (1) KR101096359B1 (fr)
CN (2) CN101326196B (fr)
AU (1) AU2006311590B2 (fr)
BR (1) BRPI0619688A2 (fr)
CA (2) CA2892180A1 (fr)
CR (2) CR10017A (fr)
EC (1) ECSP088508A (fr)
IL (2) IL190960A (fr)
MA (1) MA29975B1 (fr)
MY (1) MY154904A (fr)
NO (1) NO20082531L (fr)
NZ (2) NZ567514A (fr)
RU (1) RU2425842C2 (fr)
SG (1) SG173408A1 (fr)
UA (2) UA96139C2 (fr)
WO (1) WO2007056470A2 (fr)
ZA (2) ZA200803811B (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL212317B1 (pl) * 2003-01-31 2012-09-28 Organon Nv Sposób izolacji bialka zawierajacego wiazania disulfidowe w natywnej konformacji
EP1957531B1 (fr) * 2005-11-07 2016-04-13 Genentech, Inc. Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
CA2822302A1 (fr) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Procedes pour alterer la differenciation osteoclaste
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2655933C (fr) * 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Sequences de polynucleotides et de polypeptides impliquees dans le cancer
US8648173B2 (en) 2007-05-17 2014-02-11 Genentech, Inc. Inhibition of tumor metastasis by anti neuropilin 2 antibodies
EP3050566B1 (fr) * 2007-09-10 2018-11-28 Boston Biomedical, Inc. Groupe innovant d'inhibiteurs de la voie stat3 et d'inhibiteurs de la voie des cellules souches cancéreuses
US9808506B2 (en) 2007-10-19 2017-11-07 Rappaport Family Institute For Research In The Medical Sciences Compositions comprising semaphorins for the treatment of cancer and methods of selection thereof
EP2210092B1 (fr) * 2007-10-19 2014-06-11 Rappaport Family Institute for Research in the Medical Sciences Compositions comprenant des sémaphorines pour le traitement de maladies associées à l'angiogenèse et leurs procédés de sélection
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
SG10201608871XA (en) 2008-05-05 2016-12-29 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
BRPI0913366A8 (pt) 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
NZ603698A (en) 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
KR20110084280A (ko) 2008-11-03 2011-07-21 알레시아 바이오쎄라퓨틱스 인코포레이티드 종양 항원의 생물 활성을 특이적으로 차단하는 항체
EP2350264A4 (fr) * 2008-11-06 2012-08-29 Univ Johns Hopkins Traitement des inflammations chroniques des voies respiratoires
CA2759848C (fr) 2009-05-05 2018-12-04 Novimmune S.A. Anticorps anti-il-17f et leurs methodes d'utilisation
CA2767616A1 (fr) 2009-07-09 2011-01-13 The Scripps Research Institute Profils d'expression genique associes a une nephropathie chronique de l'allogreffe
CN102482715A (zh) * 2009-07-13 2012-05-30 霍夫曼-拉罗奇有限公司 用于癌症治疗的诊断方法和组合物
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2497498A4 (fr) * 2009-11-05 2013-04-17 Univ Osaka Agent thérapeutique pour des maladies auto-immunes ou une allergie et procédé de criblage pour l'agent thérapeutique
JP5818805B2 (ja) 2009-12-11 2015-11-18 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ−ｃ抗体及びその使用方法
ES2594893T3 (es) 2009-12-16 2016-12-23 Abbvie Biotherapeutics Inc. Anticuerpos anti HER2 y sus usos
WO2011143408A1 (fr) * 2010-05-13 2011-11-17 Genentech, Inc. Utilisation d'antagonistes de la neuropiline 1 pour le traitement du cancer
WO2011153224A2 (fr) 2010-06-02 2011-12-08 Genentech, Inc. Procédés diagnostiques et compositions de traitement du cancer
BR112012027995A2 (pt) 2010-06-18 2017-01-10 Genentech Inc anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
KR20120003187A (ko) * 2010-07-02 2012-01-10 한국생명공학연구원 Ｎｅｕｒｏｐｉｌｉｎ １ 유전자를 이용한 천식 진단 및 천식 치료제 스크리닝 방법
WO2012006503A1 (fr) * 2010-07-09 2012-01-12 Genentech, Inc. Anticorps anti-neuropiline et leurs procédés d'utilisation
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
MX346500B (es) 2010-11-10 2017-03-22 Genentech Inc * Metodos y composiciones para inmunoterapia para enfermedad neural.
RS59080B1 (sr) 2011-03-31 2019-09-30 Adc Therapeutics Sa Antitela protiv antigena 1 povezanog sa bubrezima i njihovi fragmenti koji se vezuju za antigen
EP2522341A1 (fr) 2011-05-13 2012-11-14 Tragex Pharma Compositions pharmaceutiques comportant des inhibiteurs de la neuropiline et leur utilisation dans la prévention et/ou le traitement des troubles angiogènes et des cancers
AU2012335543C1 (en) 2011-11-09 2017-12-14 Beijing Cotimes Biotech Co., Ltd., HER3 antibodies and uses thereof
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
HRP20190946T1 (hr) 2012-01-09 2019-07-26 Adc Therapeutics Sa Sredstva za liječenje trostruko negativnog raka dojke
AU2013271581B2 (en) * 2012-06-08 2018-08-09 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
AU2013329372B2 (en) * 2012-10-08 2018-07-12 St. Jude Children's Research Hospital Therapies based on control of regulatory T cell stability and function via a Neuropilin-1:Semaphorin axis
KR20180008921A (ko) 2012-11-01 2018-01-24 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
EP2983790A2 (fr) 2013-04-09 2016-02-17 Boston Biomedical, Inc. Procédés de traitement du cancer
ITMI20131351A1 (it) * 2013-08-07 2015-02-08 Biouniversa Srl Molecole leganti il recettore di bag3 per uso terapeutico.
ES2831014T3 (es) * 2014-02-18 2021-06-07 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de enfermedades mediadas por la vía de señalización del complejo NRP-1/OBR
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
JP6692816B2 (ja) * 2014-09-05 2020-05-13 アールエスイーエム，リミティド パートナーシップ 炎症を処置および予防するための組成物および方法
EP3221361B1 (fr) 2014-11-19 2021-04-21 Genentech, Inc. Anticorps multispécifiques anti-récepteur de transferrine / anti-bace1 et procédés d'utilisation
WO2016081639A1 (fr) 2014-11-19 2016-05-26 Genentech, Inc. Anticorps contre bace1 et utilisation de ceux-ci pour l'immunothérapie contre les maladies neurales
CN107108743B (zh) * 2014-12-03 2021-05-04 (株)爱恩德生物 结合神经毡蛋白1的抗体及其用途
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP6924708B2 (ja) 2015-06-29 2021-08-25 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Ｂ１ｓｐ融合タンパク質の治療薬、方法、および使用
US10688178B2 (en) 2015-06-30 2020-06-23 Osaka University AntiPlexin A1 agonist antibody
WO2017119434A1 (fr) * 2016-01-06 2017-07-13 株式会社オーダーメードメディカルリサーチ Anticorps empêchant la liaison vegf - nrp1
WO2017119435A1 (fr) 2016-01-06 2017-07-13 株式会社オーダーメードメディカルリサーチ Anticorps d'une grande affinité avec vegf
KR101985299B1 (ko) 2016-06-03 2019-09-03 삼성전자주식회사 항-c-Met/항-Nrp1 이중 특이 항체
WO2017209554A2 (fr) * 2016-06-03 2017-12-07 사회복지법인 삼성생명공익재단 Méthode de criblage d'anticorps anti-nrp1
WO2017209553A2 (fr) * 2016-06-03 2017-12-07 사회복지법인 삼성생명공익재단 Procédé de criblage d'anticorps à l'aide de cellules dérivées de patients
US11085930B2 (en) 2016-06-03 2021-08-10 Aimed Bio Inc. Anti-NRP1 antibody screening method
CA3026236C (fr) 2016-06-03 2021-01-26 Samsung Life Public Welfare Foundation Procede de criblage d'anticorps a l'aide de cellules derivees de patients
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
JOP20190134A1 (ar) * 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
CA3062656A1 (fr) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methodes pour le traitement du cancer
CN108196071A (zh) * 2018-02-09 2018-06-22 上海市第十人民医院 肝癌血清标志物nrp1
EP3758751A4 (fr) 2018-02-28 2021-11-17 Wuxi Biologics Ireland Limited. Anticorps monoclonal contre la lag-3 humaine, méthode permettant de le préparer, et utilisation de ce dernier
CA3096222A1 (fr) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions et procedes comprenant des anticorps anti-nrp2
EP3906415B1 (fr) * 2019-01-03 2026-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques permettant d'améliorer des réponses immunitaires dépendant de lymphocyte t+cd8 chez des sujets souffrant d'un cancer
CN109883932B (zh) * 2019-02-18 2021-08-10 武汉伊莱瑞特生物科技股份有限公司 流式抗体及其制备方法和滴定方法
TWI859339B (zh) * 2019-09-24 2024-10-21 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
CN114746120B (zh) * 2019-10-03 2024-07-30 Atyr医药公司 包含抗nrp2抗体的组合物和方法
WO2021138391A1 (fr) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Composés d'indazole
JP2023539428A (ja) * 2020-07-31 2023-09-14 パイントゥリー セラピューティックス インコーポレイテッド ウイルス感染症を処置するためのニューロピリンおよびアンジオテンシン変換酵素２融合ペプチド
WO2022117572A2 (fr) 2020-12-02 2022-06-09 Oncurious Nv Agoniste de ltbr utilisé pour la polythérapie contre le cancer
CN119403831A (zh) * 2022-03-30 2025-02-07 松树治疗公司 包含nrp1结合结构域的双特异性抗体及其使用方法
CA3263050A1 (fr) * 2022-07-30 2024-02-08 Pinetree Therapeutics, Inc. Compositions pour la dégradation lysosomale ciblée et leurs procédés d'utilisation
EP4403578A1 (fr) * 2023-01-19 2024-07-24 Theranovir Anticorps contre un epitope d'un neuropiline-1-peptide modifiée par glycosaminoglycane et procédés d'utilisation de celui-ci
EP4652196A1 (fr) * 2023-01-19 2025-11-26 Theranovir Anticorps à base de peptides neuropiline-1, nouvel épitope de mise en évidence associé à la neuropiline-1 modifiée par glycosaminoglycane et ses procédés d'utilisation
CN117164711B (zh) * 2023-09-28 2024-01-30 北京凯祥弘康生物科技有限公司 一种抗神经纤维丝轻链蛋白的抗体

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550362A (en) * 1895-11-26 crosby
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (fr) 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
EP0368684B2 (fr) 1988-11-11 2004-09-29 Medical Research Council Clonage de séquences d'immunoglobulines de domaines variables.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2405246A1 (fr) 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement de proteines variantes aux proprietes liantes a lterees
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (fr) 1992-04-03 1994-06-21 Ciba Geigy Ag
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
CN1701814A (zh) 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5874562A (en) 1995-06-07 1999-02-23 Progenitor, Inc. Nucleic acid encoding developmentally-regulated endothelial cell locus-1
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
EP2338915A3 (fr) 1997-04-07 2011-10-12 Genentech, Inc. Anticorps anti-VEGF
ES2292204T3 (es) * 1997-06-18 2008-03-01 MERCK & CO., INC. (A NEW JERSEY CORP.) Receptor de tipo tirosina cinasa humano, kdr.
EP0892047A3 (fr) * 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Semaphorine L humaine et murine
US6777534B1 (en) * 1997-12-09 2004-08-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
AU1810899A (en) 1997-12-09 1999-06-28 Children's Medical Center Corporation Neuropilins and use thereof in methods for diagnosis and prognosis of cancer
CA2313607A1 (fr) * 1997-12-09 1999-06-17 Children's Medical Center Corporation Fonction et utilisation de l'antagoniste du recepteur de la neuropiline
WO1999029858A1 (fr) 1997-12-09 1999-06-17 Children's Medical Center Corporation Inhibiteurs solubles du facteur de croissance de l'endothelium vasculaire et leurs utilisations
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
SI1255752T1 (sl) 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
EP1513879B1 (fr) 2002-06-03 2018-08-22 Genentech, Inc. Bibliotheques de phages et anticorps synthetiques
EP1439192A1 (fr) * 2003-01-15 2004-07-21 Xerion Pharmaceuticals AG Inhibiteurs de neuropilin-1
US6956123B2 (en) * 2003-03-17 2005-10-18 Natural Pharmaccuticals, Inc. Purification of taxanes and taxane mixtures using polyethyleneimine-bonded resins
MXPA06004853A (es) * 2003-11-07 2006-07-06 Immunex Corp Anticuerpos que se aglutinan al receptor 4 de interleucina.
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)

Also Published As

Publication number Publication date
EP2570434A2 (fr) 2013-03-20
US20130115214A1 (en) 2013-05-09
JP5197376B2 (ja) 2013-05-15
AU2006311590B2 (en) 2011-09-08
IL190960A0 (en) 2011-08-01
WO2007056470A2 (fr) 2007-05-18
NZ593289A (en) 2012-12-21
EP2570434A3 (fr) 2013-04-17
CA2629028A1 (fr) 2007-05-18
ECSP088508A (es) 2008-07-30
ZA200803811B (en) 2009-08-26
IL222922A0 (en) 2012-12-31
BRPI0619688A2 (pt) 2011-10-11
RU2425842C2 (ru) 2011-08-10
US8795660B2 (en) 2014-08-05
AU2006311590A1 (en) 2007-05-18
ZA200903718B (en) 2011-03-30
JP2011256183A (ja) 2011-12-22
NO20082531L (no) 2008-06-09
US7994286B2 (en) 2011-08-09
CR10017A (es) 2008-11-06
JP2009514972A (ja) 2009-04-09
RU2008122710A (ru) 2009-12-20
US20110256146A1 (en) 2011-10-20
EP1951758A2 (fr) 2008-08-06
UA98585C2 (uk) 2012-05-25
IL222922A (en) 2015-07-30
CN101326196B (zh) 2015-06-24
WO2007056470A3 (fr) 2007-08-09
US8211429B2 (en) 2012-07-03
UA96139C2 (uk) 2011-10-10
US20120245330A1 (en) 2012-09-27
CN101326196A (zh) 2008-12-17
US20080213268A1 (en) 2008-09-04
SG173408A1 (en) 2011-08-29
US8378080B2 (en) 2013-02-19
US20160304613A1 (en) 2016-10-20
MY154904A (en) 2015-08-28
CR20140518A (es) 2015-01-09
KR20080068105A (ko) 2008-07-22
CN102304184A (zh) 2012-01-04
CA2892180A1 (fr) 2007-05-18
IL190960A (en) 2015-01-29
KR101096359B1 (ko) 2011-12-20
NZ567514A (en) 2011-08-26

Similar Documents

Publication Publication Date Title
MA29975B1 (fr) Antagonistes de la neuropiline
FR20C1019I2 (fr) Promedicaments de composes de 2,4-pyrimidinediamine et leurs utilisations
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
EP2320940A4 (fr) Anticorps humains qui se lient au gène 3 d'activation des lymphocytes (lag-3), et leurs utilisations
EP1851238A4 (fr) Acides nucleiques d'influenza, polypeptides et leurs utilisations
EA200800952A1 (ru) Конъюгаты антитело-лекарство и способы применения
EP1920065A4 (fr) Anticorps anti-alpha v beta 6 et leurs utilisations
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
EP1778726A4 (fr) Antagonistes de l'intégrine possédant une action cytotoxique à médiation cellulaire dépendante de l'anticorps améliorée
EP2007899A4 (fr) Anticorps dirigés contre la protéine 4 du type angiopoiétine et utilisations de ceux-ci
EP1878809A4 (fr) MATERIAU DE CABLAGE EN ALLIAGE Al-Ni-B ET STRUCTURE D ELEMENT L'UTILISANT
EP2068922A4 (fr) Anticorps diriges contre il-13r alpha 1 et leurs utilisations
FR2891314B1 (fr) Bras d'injecteur anti-cokefaction.
FR2920774B1 (fr) Nouveaux derives de n-phenul acatamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contentant
EP1877795A4 (fr) Profilage diagnostique d'anticorps seriques
EP1844157A4 (fr) Stratégies pour élaborer des médicaments qui ciblent la famille d'enzymes sir2
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
ITMI20050265U1 (it) Indumento intimo ovvero capo d'abbigliamento integrante tale indumento intimo
ATE399532T1 (de) Medizinische seife
FR2920770B1 (fr) Nouveaux derives de phenylurees, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant
EP1863335A4 (fr) Polynucléotides d'eg1117 et eg307 et leurs utilisations
DOP2007000065A (es) "compuesto peptídico de actividad biológica, su preparación y sus aplicaciones"
BRPI0410638A (pt) derivados de azitromicina
FR2892921B1 (fr) Injecteur d'implant ophtalmique.
TR200600020U (tr) Üretim montajı kolay bir mobilya bağlantı elemanı